DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Desmethoxyyangonin
Desmethoxyyangonin
(12) Patent Application Publication (10) Pub. No.: US 2016/017.4603 A1 Abayarathna Et Al
Herbal Medicines in Pregnancy and Lactation : an Evidence-Based
NIH Public Access Author Manuscript Pharmacol Ther
Review Article Small Molecules from Nature Targeting G-Protein Coupled Cannabinoid Receptors: Potential Leads for Drug Discovery and Development
Kava Kava Extract Is Available from Ashland Chemical Co., Mini Star International, Inc., and QBI (Quality Botanical Ingredients, Inc.)
Kava As a Pharmacotherapy of Anxiety
Guideline for Preoperative Medication Management
Analytical Reference Standards
Cover Next Page > Cover Next Page >
Assessment Report on Piper Methysticum G. Forst., Rhizoma Based on Article 10A of Directive 2001/83/EC (Well-Established Use)
Interactions of Desmethoxyyangonin, a Secondary Metabolite from Renealmia Alpinia, with Human Monoamine Oxidase-A and Oxidase-B
Kavalactones and Flavokavins Profiles Contribute to Quality
Kava: a Review of the Safety of Traditional and Recreational Beverage Consumption
Assessment Report on Piper Methysticum G. Forst., Rhizoma Final
Kavalactones and Flavokavains in Piper Methysticum (Kava)
WHO Monographs on Selected Medicinal Plants the first Volume of the WHO Monographs on Selected Medicinal Plants, Containing 28 Monographs, Was Published in 1999
Monoamine Oxidase Inhibition by Kavalactones from Kava (Piper Methysticum)
Reference Substances for Herbal Products Our Services
Top View
Lab Analysis of Ingredients
Millennium32 Custom Field Total Kavalactone = 27.28% 29.93% Capability3, Corrected Response Factors (CF) Were Employed for Final Quantitation
AOAC SMPR® 2018.005 Standard Method Performance Requirements
Synthetic Kavalactone Analogues with Increased Potency and Selective Anthelmintic Activity Against Larvae of Haemonchus Contortus in Vitro
Animal Models of Inflammation for Screening of Anti-Inflammatory Drugs
(12) Patent Application Publication (10) Pub. No.: US 2010/0286124 A1 Gant Et Al
Herbal Contraindications & Drug Interactions
Kava-Kava- Extract
Psychoactive Substances of Natural Origin: Toxicological Aspects, Therapeutic Properties and Analysis in Biological Samples
Neuronal Signaling
Natural Compounds for the Prevention and Treatment of Cardiovascular and Neurodegenerative Diseases
Drug Interactions with Herbal Medicines
Kava As a Clinical Nutrient: Promises and Challenges
Ligand P-Gp Inhibition
Analytical Reference Standards 2012 800/654-1458 | 512/238-9129 | | 512/238-9129
Assessment of the Risk of Hepatotoxicity with Kava Products WHO Library Cataloguing-In-Publication Data
Xenosensor Regulation of Enzymes and Transporters in Drug Exposure and Disease
Phytochemical Standards Analytical Standards and Certified Reference Materials for Constituents of Medicinal Plants